Pfizer broke ground on its $236M R&D/process development facility where it will bring 450 employes together from different locations and hire 80 more in coming years.
Pfizer Inc. broke ground on its state-of-the art Research and Development (R&D) and process development facility in Chesterfield, Missouri. The new campus will bring together more than 450 employees who currently work at multiple locations in the area. Pfizer expects to hire an additional 80 employees over the coming years to support research at the site. Construction is expected to be complete by mid-2019.
The facility will provide approximately 295,000 square feet of R&D space to house Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enabling partners. This team is responsible for advancing Pfizer’s biologics, vaccines, and gene therapy portfolio by developing manufacturing processes and dosage forms applying state-of-the-art analytical technologies, conducting non-GMP manufacturing and scale-up studies. This work enables the development of potential new medicines to treat ailments in oncology, rare disease, internal medicine, inflammation & immunology, and vaccines, including biosimilars.
As part of the strategic incentives package from St. Louis County and the State of Missouri, Pfizer is donating $20,000 to the local Parkway School District to support STEM education.